Brand name · Chemotherapy / CD20 Biologic
Rituxan (Rituximab) J-Code / HCPCS Code
In short
Rituxan is billed under HCPCS J9312 — Injection, rituximab, 10 mg. One billing unit is 10 mg.
Rituximab biosimilars and rituximab with hyaluronidase have their own HCPCS codes.
Reference
- Code
- J9312 — Injection, rituximab, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Rituximab
- Pharmacologic class
- CD20-directed Cytolytic Antibody; EndoglycosidaseFrom the FDA listings below
- Labelers
- Genentech, Inc.
- J-code category
- Chemotherapy / CD20 Biologic
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Rituxanrituximab | Rituximab 10 mg/mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-051 |
| Rituxanrituximab | Rituximab 10 mg/mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-053 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Rituxan Hycelarituximab and hyaluronidase | Rituximab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-108 |
| Rituxan Hycelarituximab and hyaluronidase | Rituximab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-109 |
NDCs billed under J9312
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9312 for Rituxan. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Rituxan | 50242-0051-21 | Genentech, Inc. | 10 | 10 |
| Rituxan | 50242-0053-06 | Genentech, Inc. | 50 | 50 |